Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 19/20 | 0.80 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074675 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL2776144 | 0.79 | ROCK2 (0.83) | ROCK2ROCK1 | |
| SCHEMBL18826410 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL18826405 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL113997 | 0.76 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL2775733 | 0.76 | ROCK2 (0.77) | ROCK2ROCK1 | |
| SCHEMBL22002219 | 0.76 | ROCK2 (0.82) | ROCK2ROCK1 | |
| SCHEMBL2776673 | 0.76 | ROCK2 (0.76) | ROCK2ROCK1 | |
| SCHEMBL25773086 | 0.75 | ROCK2 (0.56) | ROCK2ROCK1 | |
| SCHEMBL25773082 | 0.75 | ROCK2 (0.56) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394826-B2 | Dual mechanism inhibitors for the treatment of disease | AERIE PHARMACEUTICALS, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | ALCON INC. (CH) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280011-A1 | DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE | RHOA, SLC6A2, ROCK2 | ROCK2 3/4885ROCK1 10/4885MEN1 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.